Browse > Article
http://dx.doi.org/10.3961/jpmph.15.022

The Economic Burden of Cancers Attributable to Metabolic Syndrome in Korea  

Kim, Dongwoo (Department of Preventive Medicine, Korea University College of Medicine)
Yoon, Seok-Jun (Department of Preventive Medicine, Korea University College of Medicine)
Gong, Young-Hoon (Department of Preventive Medicine, Korea University College of Medicine)
Kim, Young Ae (Cancer Policy Branch, National Cancer Control Institute, National Cancer Center)
Seo, Hye-Young (Department of Public Health, Graduate School of Korea University)
Yoon, Jihyun (Department of Public Health, Graduate School of Korea University)
Kim, A-Rim (Department of Public Health, Graduate School of Korea University)
Publication Information
Journal of Preventive Medicine and Public Health / v.48, no.4, 2015 , pp. 180-187 More about this Journal
Abstract
Objectives: Metabolic syndrome is an important etiologic factor in the development of certain types of cancers. The economic cost of the treatment of cancer has been steadily increasing. We therefore estimated the economic burden of cancers attributable to metabolic syndrome in Korea. Methods: We reviewed metabolic syndrome-related cancers and relative risk and then calculated population attributable fractions. We analyzed insurance claims data for metabolic syndrome-related cancers in 2012 in order to estimate the direct costs associated with these cancers, including hospitalization, outpatient visits, transportation costs, and caregivers' costs as well as indirect costs such as loss of productivity due to cancer treatment and premature death. Results: In 2012, 18 070 patients in Korea had cancers attributable to metabolic syndrome. The economic burden was USD 199.8 million and the direct and indirect costs were USD 124.5 million and USD 75.3 million, respectively. Conclusions: We estimated the economic burden of cancers attributable to metabolic syndrome in Korea and the efforts are necessary to reduce this burden.
Keywords
Metabolic syndrome; Neoplasm; Economic burden;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care 2011;34(6):1323-1328.   DOI
2 Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J 2011;35(6):561-566.   DOI
3 Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci 2011;7(7):1003-1015.   DOI
4 Bjorge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 2010;171(8):892-902.   DOI
5 Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012;35(11):2402-2411.   DOI
6 Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 2013;44(3):634-647.   DOI
7 National Health Insurance Service. National health insurance statistical yearbook 2012. Seoul: National Health Insurance Service.; 2014, p. 84 (Korean).
8 Korean Statistical Information Service. Death and death rates by cause [cited 2015 Feb 5]. Available from: http://kosis.kr/wnsearch/totalSearch.jsp (Korean).
9 Park S, Kim Y, Shin HR, Lee B, Shin A, Jung KW, et al. Population-attributable causes of cancer in Korea: obesity and physical inactivity. PLoS One 2014;9(4):e90871.   DOI
10 Kim J, Hahm MI, Park EC, Park JH, Park JH, Kim SE, et al. Economic burden of cancer in South Korea for the year 2005. J Prev Med Public Health 2009;42(3):190-198 (Korean).   DOI
11 Byun JY, Yoon SJ, Oh IH, Kim YA, Seo HY, Lee YH. Economic burden of colorectal cancer in Korea. J Prev Med Public Health 2014;47(2):84-93.   DOI
12 Haggström C, Rapp K, Stocks T, Manjer J, Bjorge T, Ulmer H, et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One 2013;8(2):e57475.   DOI
13 Ulmer H, Bjorge T, Concin H, Lukanova A, Manjer J, Hallmans G, et al. Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can). Gynecol Oncol 2012;125(2):330-335.   DOI
14 Nagel G, Bjorge T, Stocks T, Manjer J, Hallmans G, Edlinger M, et al. Metabolic risk factors and skin cancer in the Metabolic Syndrome and Cancer Project (Me-Can). Br J Dermatol 2012;167(1):59-67.   DOI
15 Levin ML. The occurrence of lung cancer in man. ActaUnioInt Contra Cancrum 1953;9(3):531-541.
16 Shin A, Park S, Shin HR, Park EH, Park SK, Oh JK, et al. Population attributable fraction of infection-related cancers in Korea. Ann Oncol 2011:22(6):1435-1442.   DOI
17 Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996, p. 20.
18 Korea Exchange Bank. The average exchange rate of 2012 [cited 2015 Feb 5]. Available from: http://www.keb.co.kr (Korean).
19 Park M, Choi Y, Tae Y, Choi J, Back S, Lee H. Health insurance patients payments survey, 2010. Seoul: National Health Insurance Corporation; 2011, p.15 (Korean).
20 Jang SC. The subjects for advancement in private employment service. Seoul: Korea Labor Institute; 2013, p. 57 (Korean).
21 Kim Y, Shin S, Park J. Costing methods in healthcare. Seoul: National Evidence-based Healthcare Collaborating Agency; 2013, p.120 (Korean).
22 Ministry of Employment and Labor. Statistics of employment and labor [cited 2015 Feb 5]. Available from: http://laborstat.molab.go.kr (Korean).
23 Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013;14(12):1165-1174.   DOI
24 Kang JH, Jeong BG, Cho YG, Song HR, Kim KA. Socioeconomic costs of overweight and obesity in Korean adults. J Korean Med Sci 2011;26(12):1533-1540.   DOI
25 Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 2014;46(2):109-123.   DOI
26 Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 2011;20(10):2006-2014.   DOI